Core Viewpoint - The company, Hema Medical (03309), announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Centre Limited, which will become a subsidiary upon completion of the acquisition expected around October 2025 [1] Group 1: Acquisition Details - The acquisition agreement was signed with three individual sellers on August 26, 2025 [1] - Hong Kong Endoscopy Centre, established in 2016, operates three endoscopy examination rooms and provides specialized medical services including gastroscopy, colonoscopy, and cystoscopy [1] - The acquisition aims to meet the market demand for high-quality medical services and is expected to enhance the company's presence in Hong Kong [1] Group 2: Strategic Rationale - The company believes that Hong Kong Endoscopy Centre has advantages in management, quality medical services, and financial performance [1] - The acquisition is anticipated to create synergies with the company's existing patient base and operations in Hong Kong and Shenzhen [1] - The board of directors considers the acquisition to be in the overall interest of the company and its shareholders [1]